- Home
- EQ vs NTRB Comparison
EQ vs NTRB Comparison
Compare EQ & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- NTRB
- Stock Information
- Founded
- EQ 2017
- NTRB 2016
- Country
- EQ United States
- NTRB United States
- Employees
- EQ N/A
- NTRB N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- EQ Health Care
- NTRB Health Care
- Exchange
- EQ Nasdaq
- NTRB Nasdaq
- Market Cap
- EQ 67.9M
- NTRB 71.8M
- IPO Year
- EQ 2018
- NTRB N/A
- Fundamental
- Price
- EQ $1.88
- NTRB $6.39
- Analyst Decision
- EQ Hold
- NTRB Buy
- Analyst Count
- EQ 2
- NTRB 1
- Target Price
- EQ $1.00
- NTRB $13.00
- AVG Volume (30 Days)
- EQ 16.1M
- NTRB 36.9K
- Earning Date
- EQ 08-14-2025
- NTRB 09-05-2025
- Dividend Yield
- EQ N/A
- NTRB N/A
- EPS Growth
- EQ N/A
- NTRB N/A
- EPS
- EQ N/A
- NTRB N/A
- Revenue
- EQ $16,553,000.00
- NTRB $2,398,437.00
- Revenue This Year
- EQ N/A
- NTRB $560.75
- Revenue Next Year
- EQ N/A
- NTRB $588.39
- P/E Ratio
- EQ N/A
- NTRB N/A
- Revenue Growth
- EQ N/A
- NTRB 18.92
- 52 Week Low
- EQ $0.27
- NTRB $2.98
- 52 Week High
- EQ $2.35
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- EQ 68.96
- NTRB 42.80
- Support Level
- EQ $1.50
- NTRB $5.81
- Resistance Level
- EQ $2.35
- NTRB $6.59
- Average True Range (ATR)
- EQ 0.35
- NTRB 0.31
- MACD
- EQ -0.00
- NTRB 0.05
- Stochastic Oscillator
- EQ 62.10
- NTRB 66.74
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.